Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to …
J Ma, L Huang, C Han - Therapeutic Advances in Medical …, 2024 - journals.sagepub.com
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
have emerged as the mainstay of treatment for advanced EGFR-mutant advanced non-small …
have emerged as the mainstay of treatment for advanced EGFR-mutant advanced non-small …
Biomarkers in non-small cell lung cancers: Indian consensus guidelines for molecular testing
K Prabhash, SH Advani, U Batra, B Biswas… - Advances in …, 2019 - Springer
Novel molecular targets and promising targeted therapies have reshaped diagnostics in
patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the …
patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the …
The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
M Lyu, J Zhou, K Ning, B Ying - OncoTargets and therapy, 2019 - Taylor & Francis
Purpose Detecting gene mutations by two competing biomarkers, circulating tumor cells
(CTCs) and ctDNA has gradually paved a new diagnostic avenue for personalized …
(CTCs) and ctDNA has gradually paved a new diagnostic avenue for personalized …
Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First …
Y Zhen, YB Xu, RY Deng, M Li, MT Ma… - … Chemistry & High …, 2024 - ingentaconnect.com
Aim: The present study is to investigate the association between T790M status and clinical
characteristics of patients with EGFR-sensitive advanced non-small cell lung cancer …
characteristics of patients with EGFR-sensitive advanced non-small cell lung cancer …
Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
Acquired resistance to epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors
(TKI s) is a prevalent clinical problem in the management of advanced non‐small‐cell lung …
(TKI s) is a prevalent clinical problem in the management of advanced non‐small‐cell lung …
Early Monitoring Drug Resistant Mutation T790M with a Two-Dimensional Simultaneous Discrimination Nanopore Strategy
J Lei, Y Huang, W Zhong, D Xiao, C Zhou - Analytical Chemistry, 2020 - ACS Publications
With the aim of detecting low frequency of drug resistant mutation T790M against wild-type
sequences, we reported a two-dimensional signal analysis strategy by combining a three …
sequences, we reported a two-dimensional signal analysis strategy by combining a three …
Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
MP Barr, AM Baird, S Halliday, P Martin, EH Allott… - Diagnostics, 2022 - mdpi.com
The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic
setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth …
setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth …
Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer—The Prospective, Randomized, Single-Blinded …
M Haentschel, M Boeckeler, I Bonzheim, F Schimmele… - Diagnostics, 2020 - mdpi.com
The detection of molecular alterations is crucial for the individualized treatment of advanced
non-small cell lung cancer (NSCLC). Missing targetable alterations may have a major …
non-small cell lung cancer (NSCLC). Missing targetable alterations may have a major …
[HTML][HTML] Scar tissue to lung cancer; pathways and treatment
Lung cancer still remains diagnosed at a late stage although we have novel diagnostic
techniques at our disposal. However; for metastatic disease we have novel therapies based …
techniques at our disposal. However; for metastatic disease we have novel therapies based …
[PDF][PDF] Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC. Diagnostics 2022 …
MP Barr, AM Baird, S Halliday, P Martin, EH Allott… - 2022 - pure.qub.ac.uk
The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic
setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth …
setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth …